Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Stock Report

| More

Biocon Biologics Takes Forward Its Mission to Unlock Universal Access to Insulins Globally

Posted On: 2019-12-03 21:36:00

Participating at IDF Congress 2019, Busan, to Engage with Key Stakeholders

Biocon Biologics, a fully integrated 'pure play' global biosimilars organisation, is taking forward its mission of unlocking affordable access to quality insulins for people with diabetes across the world. Even as we near the 100th anniversary of insulin being first used to treat a patient with diabetes, lack of equitable access to affordable insulin remains a key impediment to successful treatment for diabetes, leading to co-morbid complications and premature deaths.

Growing worldwide concern about the cost of insulin is driving the quest to find viable, long-term solutions to improve insulin access and affordability.

Biocon Biologics, committed to enabling affordable access, has launched its 'Unlock Universal Access to Quality Insulins' initiative.

In September 2019, the Company made an announcement to enable universal access to recombinant human Insulin (rh-Insulin), by offering it at less than 10 US cents / day for Governments in Low and Middle-Income Countries (LMICs). The announcement was made at a UNAIDS Health Innovation Exchange event held on the side-lines of the 74th session of the UN General Assembly in New York.

More importantly on November 14, the WHO launched its first-ever insulin prequalification pilot program to increase treatment for diabetes in LMICs. WHO prequalification of insulin is expected to boost access by increasing the flow of quality-assured products on the international market, providing countries with greater choice and patients with lower prices.

Biocon Biologics welcomes WHO's first-ever insulin prequalification program to increase treatment for diabetes in LMICs.

Biocon Biologics is now taking forward its mission to unlock affordable access to insulin at the International Diabetes Federation (IDF) Congress 2019, which is among the most significant global diabetes events and one of the largest medical congresses in the world. The theme of IDF 2019, being held in Busan, South Korea between December 2 and December 6, 2019, is 'Shape the future of diabetes.'

The IDF Congress brings together the global diabetes community to tackle a broad range of diabetes issues, from latest scientific advances to cutting-edge information on education, diabetes care, advocacy and awareness.

Christiane Hamacher, CEO, Biocon Biologics, said: "We are delighted to be participating in the International Diabetes Federation Congress for the first time. In the run-up to the 100th anniversary of insulin, Biocon Biologics has embarked on a mission to unlock universal access to high quality insulin, guided by the conviction that a lifesaving product like this needs to be accessible to patients globally, both in emerging and developed countries. Our participation at the IDF Congress is aimed at addressing current issues around insulin access, especially opportunities and value offered by biosimilars, how to achieve equitable care and sustaining India's role as pharmacy to the world. In line with our aspiration to reach 'one in five' insulin-dependent people with diabetes globally, we want to work closely with key stakeholders worldwide to find ways to ensure that insulin reaches those who need them the most."

As a credible, global insulins player, Biocon Biologics has been engaging with key stakeholders at various global forums to find ways to increase affordable access to rh-insulin and ensure the drug reaches those who need them the most. At IDF, Biocon Biologics will engage with Key Opinion Leaders (KOLs), including physicians, scientists, educators, healthcare professionals, government representatives, policy makers, and IDF members to take forward its mission to unlock affordable access to insulin.

Nearly a century after the discovery of insulin, millions of people with diabetes are denied access to this life-saving therapy due to its prohibitive costs. Insulin-dependent diabetes patients are not just finding it difficult to access insulin in emerging markets, even those in developed markets like U.S. are finding it difficult to afford insulins therapy.

As a part of its Universal Access Initiative, Biocon Biologics is organizing a symposium on '100 years of Insulin - Delivering on Universal Access & Equitable Care' during the IDF congress. This Symposium will be attended by leading KOLs and thought leaders from across the globe, including Dr Andrew Boulton, Professor at Manchester University and President Elect IDF: Dr Irl Hirsch, Professor of Metabolism, Endocrinology and Nutrition, University of Washington, U.S.; Dr Shashank Joshi, endocrinologist, diabetologist, medical researcher & IDF's South East Asia Chair-elect; and Dr Radhakrishna Sothiratnam, consultant physician, Columbia Asia Hospital, Seremban, Malaysia.

As a company committed to ensure equitable access to insulins globally, Biocon Biologics is pursuing the path of innovation to enable affordable access to human insulin to diabetes patients in need of insulin in LMICs. In line with this mission, Biocon Biologics is offering recombinant human insulin (rh-insulin) at a basic price of less than 10 US cents per day in LMICs for vials sourced by the government directly from Biocon, assuming an insulin dosage of 40 IU per day. Currently, the blended median patient prices in LMICs are US$ 9 per 10 ml vial1 translating to 36 US cents/ day. The current US list price in retail is over US$ 5 / day2.

Biocon Biologics is willing to work with governments to ensure ways to overcome price barriers, including through special pricing and setting up low-cost manufacturing facilities via public-private partnerships. The Company also seeks to work with healthcare systems and payers worldwide to ensure that insulin pricing is not a constraint to the well-being of individuals and of communities.

Despite the capital-intensive nature of insulin production, Biocon Biologics has succeeded in expanding access to insulin therapy in India and key global markets by pursuing an innovation strategy that is rooted in affordability. Biocon Biologics has one of the largest insulin manufacturing capacities in the world, which it is using to shift the access paradigm for insulin worldwide. It has cumulatively supplied over 2 billion doses of biosimilar insulins so far to patients globally over the last 15 years. In multiple countries like Mexico and Malaysia, most of the insulin-requiring diabetics take Biocon Biologics' Insulins. The Company's biosimilar insulins are also making a difference to people with diabetes in developed markets like EU, Japan and Australia.

The Company's rh-Insulin has been approved in over 40 countries and commercialized in countries like India, Mexico and Malaysia, while Insulin Glargine has been approved in over 60 markets and commercialized in countries like India, Australia, EU, Japan, UAE, South Korea, Mexico and Malaysia.

Lack of access to affordable insulin remains a key impediment to successful treatment of diabetes and results in needless complications and premature deaths, according to the World Health Organization (WHO). About 65 million people with Type 2 diabetes need insulin, but only half of them are able to access it, largely due to high prices3. All people with Type 1 diabetes need insulin to survive. The result is that high blood sugar levels have been linked to 4.2 million deaths around the world in 20194.


Over 463 Mn people have diabetes globally
4 out of 5 people with diabetes live in LMICs
1 in 2 adults with diabetes go undiagnosed (over 212 Mn people)
1 in 14 adults has impaired glucose tolerance (352 Mn people)
Over 1 Mn children and adolescents have Type 1 Diabetes
1 in 6 live births is affected by hyperglycemia in pregnancy
35% of the children and adolescents with Type 1 Diabetes come from US, India and Brazil
About 65 million people with Type 2 diabetes need insulin, but only half of them are able to access it
Diabetes currently affects over 463 million people worldwide and this number is projected to reach 578 million by 2030, and 700 million by 20454

Shares of BIOCON LTD. was last trading in BSE at Rs.283.05 as compared to the previous close of Rs. 285.95. The total number of shares traded during the day was 788158 in over 8993 trades.

The stock hit an intraday high of Rs. 299.7 and intraday low of 283.05. The net turnover during the day was Rs. 228266488.

1. BMJ Global Health 2019: Insulin Prices Availability and affordability in 13 LMICs.
3. WHO
4. IDF Diabetes Atlas 2019

Source: Equity Bulls

Click here to send ur comments or to

Other Headlines:

Daily market commentary - 24th January 2020 - BONANZA PORTFOLIO LTD

IndiGo launches direct connection between Delhi and Bangkok

mBAJA & eBAJA Design and Technical Evaluation and Dynamic Events held today for BAJA SAEINDIA 2020

Wendt India Ltd announces Q3, 9MFY20 results

ABM Knowledgeware Ltd Q3 consolidated net profit slips to Rs. 3.08 crore

Prestige Estates Projects Ltd consolidated Q3 net profit climbs to Rs. 161.8 crore

EIH Ltd Q3 net profit higher QoQ, YoY

Bank of Baroda reports loss in Q3 FY2020

Eldeco Housing and Industries Ltd announces Q3, 9MFY20 results

BEML CMD gets Most Admired Leader Award

Siemens Ltd to acquire 99.22% in C&S Electric Ltd for Rs. 2100 crore

VST Tillers Tractors Ltd enters into MOU with Zetor Tractors

NHPC declared successful resolution applicant for Jalpower Corporation Ltd

L&T raises Rs. 1000 crore through 6.72% NCDs

Solapur Tollways Pvt Ltd receives completion certificate for part of NH-9 project

Cipla gets 4 observations from USFDA for API facility at Bommasandra, Bangalore

ALLSEC Technologies Ltd consolidated Q3 FY20 net profit at Rs. 8.55 crore

Wendt India Ltd Q3 consolidated PAT falls to Rs. 2.20 crore

Faze Three Autofab Ltd Q3 net profit at Rs. 0.48 crore

Emkay Global Financial Services Ltd Q3 loss at Rs. 1.41 crore

ION Exchange India Ltd consolidated Q3 PAT higher at Rs. 26.31 crore

Shree Bhavya Fabrics Ltd posts net profit of Rs. 0.77 crore in Q3

Mangalam Drugs & Organics Ltd Q3 PAT jumps to Rs. 1.65 crore

ARO Granite Industries Ltd Q3 net profit at Rs. 0.65 crore

JSW Steel Ltd consolidated Q3 PAT declines to Rs. 211 crores

Udaipur Cement Works Ltd posts PAT of Rs. 0.97 crore in Q3

Strides announces successful completion of US FDA inspection at its Alathur facility with Zero 483 observations

Sonata Software Ltd reports Rs.75.86 crores net profit in Q3 FY20

Oriental Hotels Ltd posts consolidated PAT of Rs. 7.31 crore

Kirloskar Ferrous Industries Ltd Q3 PAT increases QoQ to Rs. 23.33 crore

Indian Bank reports Q3 net profit of Rs. 247.16 crore

Sunil Agro Foods Ltd posts net profit of Rs. 0.14 crore in Q3

Triumph Motorcycles and Bajaj Auto commence their global partnership

AMJ Land Holdings Ltd reports consolidated profit of Rs. 4 crore in Q3

Onward Technologies Ltd Q3 net profit drops QoQ, YoY

Oriental Veneer Products Ltd Q3 consolidated PAT jumps to Rs. 8.71 crore

USFDA conducts surprise audit at bioanalytical facility of Jeevan Scientific Technology Ltd

ULTRATECH Cement Ltd Q3 consolidated net profit soars to Rs. 711.25 crores

CG-VAK Software & Exports Ltd Q3 consolidated PAT rises to Rs. 0.94 crore

Atishay Ltd bags work order

ATUL Ltd consolidated Q3 net profit declines QoQ

AAVAS Financiers Ltd Q3 consolidated PAT drops QoQ to Rs. 67.92 crore

NLC India Ltd to raise Rs. 525 crore

Supreme Industries Ltd reports consolidated PAT of Rs. 123.39 crores in Q3

HCL Technologies Honors Global Goodwill Champions at the 2020 World Economic Forum in Davos

A true symbol of Make in India, Maruti Suzuki commences exports of its blockbuster model S-PRESSO

Allahabad Bank board approves capital infusion of Rs. 2153 crore

TCS Named a Leader in Talent Readiness for Next-generation IT Services by Everest Group

Strides receives USFDA tentative approval for Triamcinolone Acetonide Ointment

Alembic Pharmaceuticals announces USFDA Final Approval for Bosentan Tablets, 62.5 mg and 125 mg

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019